Skip to main content
spacbrain

CITIUS ONCOLOGY, INC.

Closed (deSPAC)

Health Care · oncology immunotherapy drug development · founded 2021

What it is
Oncology, Inc
What it’s doing now
Merging with TenX Keane Acquisition (TENK) — closed (despac).
What you should know
Data is still being assembled for this company — what is shown below is everything we have verified so far.

The business, per its filings

SEC primary

Oncology, Inc. Citius Oncology is a late-stage pharmaceutical company focused on developing and commercializing targeted oncology therapies. Its strategy centers on achieving a market leading position by advancing innovative therapies with reduced development and clinical risks, and leveraging competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. Citius Oncology’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. Management believes the market for LYMPHIR for CTCL, estimated to exceed $400 million, is attractive, growing and underserved by existing treatments. On July 28, 2023, the FDA issued a complete response letter (CRL) in response to the LYMPHIR BLA. The FDA is requiring enhanced product testing and additional controls agreed to with the FDA during the market application review. There were no concerns relating to the safety and efficacy of the clinical data package submitted with the BLA, or the proposed prescribing information. In September 2023, Citius Pharma announced that the FDA has agreed with the plans to address the requirements outlined in the CRL. This guidance has clarified the path forward in completing the necessary activities to support the resubmission of the BLA for LYMPHIR. The BLA resubmission is anticipated in early 2024. Citius Oncology was founded in August 2021 as Citius Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Citius Pharma and began operations in April 2022. The corporate na

Source: S-4/A, accession 0001493152-24-026883

What the company says about itself

Web research — not audited
What our web check found

[WEB-INTEL 2026-08-26] 7 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "up to $36.5 million in debt and equity capital secured" [https://www.prnewswire.com/news-releases/citius-oncology-inc-reports-fiscal-second-quarter-2026-financial-results-and-provides-business-update-302773892.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Cash and cash equivalents of $2.6 million as of March 31, 2026, prior to the up to $36.5 million concurrent debt and equity financings that closed in early May 2026" [https://www.prnewswire.com/news-releases/citius-oncology-inc-reports-fiscal-second-quarter-2026-financial-results-and-provides-business-update-302773892.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "$10 million funded at close on May 6, 2026" [https://www.prnewswire.com/news-releases/citius-oncology-inc-reports-fiscal-second-quarter-2026-financial-results-and-provides-business-update-302773892.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Avenue Capital Group to provide up to $25 Million via Senior Credit Facility with an initial $10 million tranche funded at closing" [https://www.prnewswire.com/news-releases/citius-oncology-inc-secures-up-to-36-5-million-in-debt-and-equity-capital-to-accelerate-lymphir-commercialization-302763264.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Gross proceeds of approximately $11.5 million secured by a concurrent exercise of certain outstanding warrants held by single healthcare-focused institutional investor" [https://www.prnewswire.com/news-releases/citius-oncology-inc-secures-up-to-36-5-million-in-debt-and-equity-capital-to-accelerate-lymphir-commercialization-302763264.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The new warrant offering is expected to close on or about May 6, 2026" [https://www.prnewswire.com/news-releases/citius-oncology-inc-secures-up-to-36-5-million-in-debt-and-equity-capital-to-accelerate-lymphir-commercialization-302763264.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Citius Oncology, Inc. announced that it will raise $36.5 million in a round of funding from new lenders Avenue Venture Opportunities Fund II, L.P., May 5, 2026" [https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ctor/citius-oncology]

Source: company web presence · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

CITIUS ONCOLOGY, INC. is merging with TenX Keane Acquisition (TENK) currently marked Closed (deSPAC).

Headline equity value—

Structure per SEC accession(s) 0001493152-23-040532. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is CITIUS ONCOLOGY, INC. going public?

CITIUS ONCOLOGY, INC. has an approved merger with the SPAC TenX Keane Acquisition (TENK). Deal status: Closed (deSPAC).

Does CITIUS ONCOLOGY, INC. have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other health care deals